443924-74-1

Basic information

• Product Name: 5-(2,5-dimethylphenoxy)pentanoic acid
• Synonyms: 5-(2,5-dimethylphenoxy)pentanoic acid
• CAS NO: 443924-74-1
• Molecular Weight: 222.284
• Mol File: 443924-74-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-(2,5-dimethylphenoxy)pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2,5-dimethylphenoxy)pentanoic acid(443924-74-1)
• EPA Substance Registry System: 5-(2,5-dimethylphenoxy)pentanoic acid(443924-74-1)

Safety Data

• Hazardous Substances Data: 443924-74-1(Hazardous Substances Data)

Upstream product

• 4509-90-4 5-bromovaleroyl chloride 
• 2067-33-6 5-bromopentanoic acid 
• 95-87-4 2,5-Dimethylphenol 
• 13931-39-0 isobutyl 5-bromopentanoate 
• 14660-52-7 ethyl 5-bromovalerate 
• 443924-70-7 ethyl 5-(2,5-dimethylphenoxy)pentanoate 
• 38585-38-5 sodium 2,5-dimethylphenolate 

Downstream Products

• 443924-75-2 5-(2,5-dimethyl-phenoxy)-pentanoyl chloride 
• 443924-76-3 (S)-3-[5-(2,5-Dimethyl-phenoxy)-pentanoyl]-4-isopropyl-oxazolidin-2-one 

Relevant articles and documents

Gemfibrozil derivatives as activators of soluble guanylyl cyclase – A structure-activity study

Previous studies demonstrated that anti-hyperlipidemic drug gemfibrozil acts as NO- and heme-independent activator of NO receptor soluble guanylyl cyclase. A series of new gemfibrozil derivatives were synthesized and evaluated for sGC activation. The structure-activity relationship study identified the positions in gemfibrozil's scaffold that are detrimental for sGC activation and those that are amendable for optimizing modifications. Compared with gemfibrozil, compounds 7c and 15b were more potent activators of cGMP-forming activity of purified sGC and exhibited enhanced relaxation of preconstricted mouse thoracic aorta rings. These studies established the overall framework needed for futher improvement of sGC activators based on gemfibrozil scaffold.

Synthesis and antiplatelet activity of gemfibrozil chiral analogues

The chiral analogues of gemfibrozil 5-(2,5-dimethylphenoxy)-2-methylpentanoic acid and 5-(2,5-dimethylphenoxy)-2-ethylpentanoic acid were synthesized in optically active form using (S)-4-(1-methylethyl)-2-oxazolidinone as chiral auxiliary. All compounds inhibit human platelet aggregation. From these data, one can surmise that all tested compounds and gemfibrozil act at the platelet level with different mechanism than that of ASA, even if with a different potency.